Drug Trial Radar · NCT07108036
A Study to Assess Anktiva in Patients With Long Covid-19.
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 14, 2025
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Conditions
- Long COVID
Interventions
N-803 (IL-15 Superagonist)Drug
N-803 administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
- Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
- Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
- Incidence of abnormal changes in safety laboratory tests (CBC and CMP).Time frame: Through the end of the study treatment period (approximately 75 days)
- Clinically important changes in vital signs.Time frame: Through the end of the study treatment period (approximately 75 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California - San Francisco
San Francisco, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.